Predictors of Clinical Response of Non-Small Cell Cancer to Gefitinib [4] (multiple letters)

JAMA

Volumn 291, Issue 13, 2004, Pages 1563-1564

  Ardizzoni, Andrea ^a   Tiseo, Marcello ^a   Kris, Mark G ^b   Kay, Andrea C ^c   Ochs, Judith J ^c   Wolf, Michael K ^c  

^a UNIVERSITY OF GENOA   (Italy)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN DERIVATIVE; DOCETAXEL; ENDOTHELIAL CELL GROWTH FACTOR; GEFITINIB; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; QUINAZOLINE DERIVATIVE;

ADENOCARCINOMA; DISEASE COURSE; DRUG EFFECT; GENDER; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; LUNG NON SMALL CELL CANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; DRUG ANTAGONISM; LUNG TUMOR; NOTE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; ENZYME INHIBITORS; HUMANS; LUNG NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 18244412283     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.291.13.1563-a     Document Type: Letter

References (0)